An observational study in Hemophilia B, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 17 sites in 4 countries. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Regeneron Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Hemophilia B with a site in United States — 16 open to participants now, 22 under way, 9 of them phase 3. Hemophilia B · United States.
Among the 120 studies in Hemophilia B with a site in United States, this one is the 32nd largest by enrollment of the 39 observational ones that give a count, is one of 6 that started in 2024, is one of 39 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 103rd registered.
292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.
Browse Hemophilia B studies →16 of the 120 studies in Hemophilia B with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 6+
Pfizer · Sites in United States
Ages 12–74
CSL Behring · Sites in United States, Australia, Austria and 5 more countries
Ages 138 mo–206 mo · Men only
American Thrombosis and Hemostasis Network · Sites in United States
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 6 more countries
Ages 2+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Hemophilia B studies recruiting now, 18 (58%) set no upper age limit and 11 (35%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 16 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 22 · Phase 3 42 · Phase 4 4
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 86 across 108 observational studies indexed under Hemophilia B.
Median enrollment 30 across the 81 interventional studies, 64 across the 39 observational. Of the 94 that completed or were terminated, 40 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 120 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Hemophilia B — fewer than ten, so there is no comparison to draw.
2 of the studies in Hemophilia B with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05568459Regeneron PharmaceuticalsA Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy | 2026-11-20 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Hemophilia B with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program to understand and treat Hemophilia B with a potential experimental new therapy in the future. There is no obligation to agree to taking part in this future study.
The study is looking to answer several other research questions to help understand each participant's individual disease characteristics, including:
Male patients with Hemophilia B with a history of FIX:C ≤2% or a documented genotype known to produce severe hemophilia B on current FIX Replacement Therapy prophylaxis
Key Inclusion Criteria:
Key Exclusion Criteria:
If any of the following pre-existing diagnoses are documented:
NOTE: Other Inclusion/Exclusion Protocol Defined Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male participants with hemophilia B on current FIX Replacement Therapy prophylaxis or a documented genotype known to produce severe hemophilia B
Other: Non-Interventional
No study treatment will be administered in this study.
Annualized bleeding rate (ABR)
Time frame: At least 26 Weeks Up to 96 weeks
Annualized utilization (IU/kg) of FIX replacement therapy
Time frame: Up to 96 Weeks
FIX functional (coagulant) activity (FIX:C) in participants on prophylaxis FIX replacement therapy
FIX:C includes pre-dose and average activity
Time frame: Through the end of the study, approximately 96 Weeks
Difference of FIX:C in participants on prophylaxis FIX replacement therapy by one-stage and chromogenic assays
Time frame: Through the end of the study, approximately 96 weeks
Difference of FIX:C between one-stage assay and chromogenic substrate assay by laboratory in participants on prophylaxis FIX replacement therapy
Time frame: Through the end of the study, approximately 96 weeks
Difference of FIX:C between laboratories by assay (one-stage assay and chromogenic substrate assay) in participants on prophylaxis FIX replacement therapy
Time frame: Through the end of the study, approximately 96 weeks
Incidence of adverse event (AEs)
Time frame: Through the end of the study, approximately 96 Weeks
Severity of AEs
Time frame: Through the end of the study, approximately 96 Weeks
Hemophilia Quality of Life (Haemo-Qol-A) total and individual domain scores
The Haemo-QoL-A is a self-reported Hemophilia-specific health-related quality of life questionnaire which consists of 41 questions covering 6 domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact, and Treatment Concerns). Items are answered on a 6-point Likert-type scale, ranging from 0 (None of the time) to 5 (All of the time). Higher scores mean better health-related quality of life or less impairment.
Time frame: Up to 96 Weeks
Hemophilia Activities List (HAL) total and individual scores
HAL measures of the impact of Hemophilia on functional abilities in adults. The questionnaire consists of 42 items across 7 domains. Each item is rated on a scale of 1 (Impossible) to 6 (Never). Higher scores represent lower levels of activity limitations.
Time frame: Up to 96 Weeks
European Quality of Life 5 Dimensions 3-levels (EQ-5D-3L) score
EQ-5D-3L health questionnaire is a participant/relative answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. the status of each dimension had 3 possible responses (1 =no problem, 2 some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition.
Time frame: Up to 96 Weeks
Hemophilia Joint Health Score (HJHS) total and individual scores per joint
The examination involves a physical assessment of elbow, knee, and ankle joints. Individual joints are scored based on duration and presence of swelling, joint pain, flexibility, muscle atrophy, strength, and overall gait. The HJHS is a validated 11-item scoring tool based on radiologic and clinical evaluation, sensitive to detect early signs and minor changes. HJHS ranges from 0 to 124. Higher values in the HJHS represent worse situation for the participant.
Time frame: Up to 96 Weeks
Annualized medically attended visit (MAV) rate for any reason
The annual rate of MAVs including emergency room (ER) visits, urgent care center visits, physician's office visits, telemedicine visits, or hospitalizations related to bleeds treated on-demand with FIX replacement therapy
Time frame: Up to 96 Weeks
Detection of antibodies to adeno-associated virus (AAV) capsid proteins
Time frame: Up to 96 Weeks
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.
Of 42 observational studies under Hemophilia B, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 105. This study's planned 34 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.